ATE429224T1 - Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor - Google Patents

Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor

Info

Publication number
ATE429224T1
ATE429224T1 AT06114684T AT06114684T ATE429224T1 AT E429224 T1 ATE429224 T1 AT E429224T1 AT 06114684 T AT06114684 T AT 06114684T AT 06114684 T AT06114684 T AT 06114684T AT E429224 T1 ATE429224 T1 AT E429224T1
Authority
AT
Austria
Prior art keywords
preotease
hiv
inhibitor
preparations containing
medicinal preparations
Prior art date
Application number
AT06114684T
Other languages
English (en)
Inventor
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23269615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE429224(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE429224T1 publication Critical patent/ATE429224T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06114684T 1999-06-04 2000-05-25 Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor ATE429224T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32582699A 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
ATE429224T1 true ATE429224T1 (de) 2009-05-15

Family

ID=23269615

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00937743T ATE332132T1 (de) 1999-06-04 2000-05-25 Verbesserte arzneizubereitungen enthaltend ritonavir
AT06114684T ATE429224T1 (de) 1999-06-04 2000-05-25 Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00937743T ATE332132T1 (de) 1999-06-04 2000-05-25 Verbesserte arzneizubereitungen enthaltend ritonavir

Country Status (32)

Country Link
EP (2) EP1733725B2 (de)
JP (1) JP4753511B2 (de)
KR (1) KR100815412B1 (de)
CN (2) CN101361723B (de)
AR (2) AR032586A1 (de)
AT (2) ATE332132T1 (de)
AU (1) AU778198B2 (de)
BG (1) BG65445B1 (de)
BR (1) BR0007294A (de)
CA (1) CA2371109C (de)
CL (1) CL2008003491A1 (de)
CO (1) CO5160323A1 (de)
CY (2) CY1105237T1 (de)
CZ (1) CZ301308B6 (de)
DE (2) DE60042092D1 (de)
DK (2) DK1733725T4 (de)
ES (2) ES2324549T5 (de)
HU (1) HU229501B1 (de)
IL (3) IL146025A0 (de)
MX (1) MXPA01012478A (de)
MY (1) MY127908A (de)
NO (1) NO328968B1 (de)
NZ (1) NZ515016A (de)
PL (1) PL197671B1 (de)
PT (2) PT1733725E (de)
SA (1) SA00210237B1 (de)
SI (2) SI1183026T1 (de)
SK (2) SK286305B6 (de)
TR (1) TR200103488T2 (de)
TW (1) TWI244390B (de)
WO (1) WO2000074677A2 (de)
ZA (1) ZA200108641B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5090830A1 (es) * 1998-07-20 2001-10-30 Abbott Lab Poliformo de un agente farmaceutico
DK1733725T4 (da) * 1999-06-04 2012-09-17 Abbott Lab Farmaceutiske formuleringer omfattende mindst én HIV-proteaseinhiberende forbindelse
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
EP1175205B1 (de) 1999-11-12 2006-06-14 Abbott Laboratories Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
BR0011864A (pt) * 2000-01-19 2004-07-20 Abbott Lab Formulações farmacêuticas
JP2005508294A (ja) * 2001-05-25 2005-03-31 アボット・ラボラトリーズ リトナビルおよび／またはロピナビルを含む軟弾性カプセル
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
AP2702A (en) * 2005-12-30 2013-07-23 Gilead Sciences Inc Methods for improving the pharmacokinetics of HIV integrase inhibitors
AU2015258296B2 (en) * 2006-07-07 2017-08-17 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2015234299B2 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
PT2049506E (pt) * 2006-07-07 2015-10-09 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
AU2013204805C1 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
NO345893B1 (no) * 2006-07-07 2021-09-27 Gilead Sciences Inc Modulatorer av farmakokinetikkegenskaper til terapeutika
EP2112925A4 (de) 2006-11-15 2013-01-09 Abbott Lab Formulierungen mit fester pharmazeutischer dosierung
RS55280B1 (sr) 2007-02-23 2017-03-31 Gilead Sciences Modulatori farmakokinetičkih svojstava lekova
AU2013204817B2 (en) * 2007-02-23 2015-05-07 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
BRPI0807581A2 (pt) * 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
AU2015204378B2 (en) * 2007-02-23 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
TWI448457B (zh) * 2007-07-06 2014-08-11 Gilead Sciences Inc 治療劑的藥物動力學性質之調節劑
ES2555209T3 (es) 2008-01-04 2015-12-29 Gilead Sciences, Inc. Inhibidores del citocromo P450
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL110752A (en) † 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ES2270426T3 (es) * 1994-03-18 2007-04-01 Supernus Pharmaceuticals, Inc. Sistema de suministros de farmacos emulsionados.
DE4431489A1 (de) * 1994-09-03 1996-03-07 Heidelberger Baustofftech Gmbh Schnellhärtende aminosilanvernetzende Silikonmassen
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
JP2000502997A (ja) * 1995-12-13 2000-03-14 アボツト・ラボラトリーズ レトロウイルスプロテアーゼ抑制化合物
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
CO5090830A1 (es) * 1998-07-20 2001-10-30 Abbott Lab Poliformo de un agente farmaceutico
DK1733725T4 (da) * 1999-06-04 2012-09-17 Abbott Lab Farmaceutiske formuleringer omfattende mindst én HIV-proteaseinhiberende forbindelse

Also Published As

Publication number Publication date
IL216686A (en) 2014-01-30
CY1109135T1 (el) 2014-07-02
SI1733725T2 (sl) 2012-10-30
CA2371109A1 (en) 2000-12-14
ES2324549T3 (es) 2009-08-10
NO20015670D0 (no) 2001-11-20
CY1105237T1 (el) 2010-03-03
ES2324549T5 (es) 2012-10-31
KR100815412B1 (ko) 2008-03-20
NO20015670L (no) 2001-11-20
HUP0201591A3 (en) 2002-10-28
PT1733725E (pt) 2009-06-30
SK17202001A3 (sk) 2002-03-05
WO2000074677A2 (en) 2000-12-14
SI1733725T1 (sl) 2009-08-31
DE60042092D1 (de) 2009-06-04
KR20020011994A (ko) 2002-02-09
IL216686A0 (en) 2012-01-31
CZ301308B6 (cs) 2010-01-06
BR0007294A (pt) 2002-08-27
JP4753511B2 (ja) 2011-08-24
EP1733725B2 (de) 2012-08-08
CN100418527C (zh) 2008-09-17
DE60029219D1 (de) 2006-08-17
EP1733725B1 (de) 2009-04-22
EP1733725A1 (de) 2006-12-20
PT1183026E (pt) 2006-11-30
CL2008003491A1 (es) 2009-03-06
SA00210237B1 (ar) 2006-11-07
NO328968B1 (no) 2010-06-28
HU229501B1 (hu) 2014-01-28
DK1733725T3 (da) 2009-08-03
ES2265946T3 (es) 2007-03-01
AU5287700A (en) 2000-12-28
HK1045804A1 (en) 2002-12-13
SK287185B6 (sk) 2010-02-08
BG65445B1 (bg) 2008-08-29
CN1353607A (zh) 2002-06-12
TR200103488T2 (tr) 2002-04-22
AR064309A2 (es) 2009-03-25
MXPA01012478A (es) 2003-10-14
DE60029219T2 (de) 2007-06-28
JP2003501386A (ja) 2003-01-14
DK1183026T3 (da) 2006-11-06
IL146025A (en) 2012-04-30
CZ20014293A3 (cs) 2002-03-13
NZ515016A (en) 2004-02-27
AU778198B2 (en) 2004-11-25
CA2371109C (en) 2011-04-26
CO5160323A1 (es) 2002-05-30
EP1183026B1 (de) 2006-07-05
WO2000074677A3 (en) 2001-02-22
PL351943A1 (en) 2003-07-14
CN101361723B (zh) 2013-11-06
DK1733725T4 (da) 2012-09-17
EP1183026A2 (de) 2002-03-06
TWI244390B (en) 2005-12-01
HUP0201591A2 (en) 2002-09-28
CN101361723A (zh) 2009-02-11
AR032586A1 (es) 2003-11-19
ATE332132T1 (de) 2006-07-15
IL146025A0 (en) 2002-07-25
PL197671B1 (pl) 2008-04-30
SI1183026T1 (sl) 2006-10-31
BG106239A (en) 2002-08-30
MY127908A (en) 2006-12-29
SK286305B6 (en) 2008-07-07
ZA200108641B (en) 2003-01-20

Similar Documents

Publication Publication Date Title
ATE429224T1 (de) Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor
ATE392890T1 (de) Hydrogel-gesteuerte dosierungsform
NO20071303L (no) Farmasoytiske preparater
IS6040A (is) Valdekoxib efnablöndur
ITTO20010008A0 (it) Formulazione farmaceutica
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
DE60011853D1 (de) Injektionsspritze
EE200200038A (et) Konservitud farmatseutilised preparaadid
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
NO992339L (no) Farmasöytiske formuleringer
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
NO992692L (no) Nefadozon doseringsform
NO20014926D0 (no) Farmasöytiske forbindelser
ITMI20001827A0 (it) Medicamento antinfiammatorio
DE69926012D1 (de) Arzneizubereitungen
AR025867A1 (es) Formulacion portasdora farmaceutica
DE59902159D1 (de) Aktiver mikromischer
EE200100697A (et) Farmatseutiline kompleks
DE69906934D1 (de) Arzneizubereitungen
EP1142589A4 (de) Medizinische zusammensetzungen
NO20004816D0 (no) Ny farmasøytisk formulering
DE50009295D1 (de) Vernetzerfreie zubereitungen
IT1318654B1 (it) Composizioni farmaceutiche comprendenti agenti antiinfiammatori e lorousi.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1733725

Country of ref document: EP